ABCB1 overexpression in cancers contributes to reduced intracellular chemotherapeutics accumulation and brings about resistance against a wide variety of the recently available antineoplastic agents like taxanes (docetaxel), vinca alkaloids (vinblastine), and anthracyclines (doxorubicin) (8–11). This evidence concerns the gene ABCB1 and cancer.